Reversal of haemorrhagic shock in rats by cholinomimetic drugs
British Journal of Pharmacology, ISSN: 0007-1188, Vol: 98, Issue: 1, Page: 218-224
1989
- 41Citations
- 5Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations41
- Citation Indexes41
- 41
- CrossRef32
- Captures5
- Readers5
Article Description
In an experimental model of haemorrhagic shock resulting in the death of all rats within 20-30 min, the intravenous (i.v.) injection of the tertiary amine cholinesterase inhibitor physostigmine (17-70 μg kg) induced a prompt, sustained and dose-dependent improvement of cardiovascular and respiratory function, with marked increase in the volume of circulating blood and survival of all treated animals, at least for the 2 h of observation. Similar results were obtained with the i.v. injection of the cholinoceptor agonist oxotremorine (5-25 μg kg), while neostigmine (54 or 70 μg kg), a quaternary cholinesterase inhibitor which cannot cross the blood-brain barrier, had negligible effects. The anti-shock activities of oxotremorine and physostigmine were blocked by the intracerebroventricular injection of either of the combined nicotinic and M-muscarinic receptor antagonists gallamine and pancuronium, or of the nicotinic antagonist mecamylamine. They were also blocked by intraperitoneal injection of the adrenergic neurone blocking agent guanethidine, but they were not antagonized by either the combined M- and M-muscarinic receptor antagonist atropine, the M-muscarinic receptor antagonist pirenzepine, or the M-muscarinic receptor antagonist 4-diphenylacetoxy-N-methylpiperidine methobromide. It is concluded that cholinomimetic drugs can reverse hypovolaemic shock through central activation (seemingly mediated by nicotinic receptors) of sympathetic tone, with mobilization and redistribution of the residual blood.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0024407590&origin=inward; http://dx.doi.org/10.1111/j.1476-5381.1989.tb16885.x; http://www.ncbi.nlm.nih.gov/pubmed/2804546; https://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.1989.tb16885.x; https://dx.doi.org/10.1111/j.1476-5381.1989.tb16885.x; https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1476-5381.1989.tb16885.x
Wiley
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know